信邦制药
(002390)
| 流通市值：69.46亿 | | | 总市值：72.89亿 |
| 流通股本：18.52亿 | | | 总股本：19.44亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,441,207,780.35 | 6,032,262,052.57 | 4,565,355,757.09 | 3,046,569,827.96 |
| 营业收入 | 1,441,207,780.35 | 6,032,262,052.57 | 4,565,355,757.09 | 3,046,569,827.96 |
| 二、营业总成本 | 1,378,738,264.35 | 5,712,473,384.68 | 4,276,861,231.49 | 2,859,294,464.95 |
| 营业成本 | 1,209,422,451.4 | 4,996,367,504.59 | 3,724,210,514.97 | 2,501,166,385.53 |
| 税金及附加 | 6,857,481.57 | 25,012,693.95 | 18,996,760.34 | 11,885,860.27 |
| 销售费用 | 66,084,428.65 | 305,691,534.82 | 229,262,839.63 | 146,659,961.12 |
| 管理费用 | 91,663,427.16 | 364,211,686.05 | 287,369,213.5 | 188,429,729.92 |
| 研发费用 | 709,842.91 | 4,586,715.51 | 3,824,833.2 | 2,155,422.34 |
| 财务费用 | 4,000,632.66 | 16,603,249.76 | 13,197,069.85 | 8,997,105.77 |
| 其中:利息费用 | 5,788,226.69 | 23,538,286.46 | 18,569,510.71 | 12,593,004.89 |
| 其中:利息收入 | 2,002,690.72 | 7,835,746.67 | 6,002,045.76 | 4,035,891.14 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 101,384.14 | 2,926,543.94 | 1,300,500.19 | - |
| 资产处置收益 | 41,126.11 | -2,291,981.97 | -25,311.75 | -9,669.8 |
| 资产减值损失(新) | - | -3,985,503.75 | - | - |
| 信用减值损失(新) | -1,582,518.96 | -67,628,076.48 | -25,821,346.09 | -21,706,722.3 |
| 其他收益 | 736,396.73 | 6,037,827.9 | 3,296,082.51 | 2,198,410.45 |
| 四、营业利润 | 61,765,904.02 | 254,847,477.53 | 267,244,450.46 | 167,757,381.36 |
| 加:营业外收入 | 249,870.78 | 13,100,866.38 | 735,020.83 | 595,473.35 |
| 减:营业外支出 | 921,303.62 | 82,446,846.67 | 3,707,307.6 | 2,264,885.7 |
| 五、利润总额 | 61,094,471.18 | 185,501,497.24 | 264,272,163.69 | 166,087,969.01 |
| 减:所得税费用 | 7,233,429.38 | 29,811,440.25 | 31,534,618.66 | 14,647,709.58 |
| 六、净利润 | 53,861,041.8 | 155,690,056.99 | 232,737,545.03 | 151,440,259.43 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 53,861,041.8 | 155,681,230.01 | 232,737,545.03 | 151,440,259.43 |
| 终止经营净利润 | - | 8,826.98 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 41,244,211.17 | 101,381,622.75 | 176,589,574.9 | 114,879,289.31 |
| 少数股东损益 | 12,616,830.63 | 54,308,434.24 | 56,147,970.13 | 36,560,970.12 |
| 扣除非经常损益后的净利润 | 41,075,434.6 | 165,318,585.59 | 175,237,268.06 | 114,851,463.77 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.05 | 0.09 | 0.06 |
| (二)稀释每股收益 | 0.02 | 0.05 | 0.09 | 0.06 |
| 九、综合收益总额 | 53,861,041.8 | 155,690,056.99 | 232,737,545.03 | 151,440,259.43 |
| 归属于母公司股东的综合收益总额 | 41,244,211.17 | 101,381,622.75 | 176,589,574.9 | 114,879,289.31 |
| 归属于少数股东的综合收益总额 | 12,616,830.63 | 54,308,434.24 | 56,147,970.13 | 36,560,970.12 |
| 公告日期 | 2025-04-30 | 2025-04-15 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |